Skip Ribbon Commands
Skip to main content
Researchers
  • Prof.  Gershon Golomb
Prof Gershon Golomb
 
Scientific Interest  
 

        ·   Drug delivery and therapy in cardiovascular disorders. 

        ·   Controlled release implantable and injectable drug delivery systems.  

        ·   Dosage forms and formulations.  

        ·  Targeted nanoparticles (polymeric-based and liposomes) in cancer and cardiovascular disorders. 

        ·   Gene, antisense, siRNA and protein delivery and therapy.  

        ·   Nanoparticles, Nanospheres, Liposomes, Matrices, Bisphosphonates.

        ·   Modulation of the Innate Immunity (monocytes, macrophages). 

 

 
Research Projects  
 

 ·   Anti-inflammatory Effects by Nanoparticles of Bisphosphonates Affecting Monocytes and Macrophages.  

 ·   Targeted Nanoparticles of Antisenses and siRNA in Mammary Carcinoma. 

 ·   Imunomodulation of the Innate-immunity by Liposomal Delivery Systems for Endometriosis Therapy.  

 ·   Blood Brain Barrier Transport of Nanoparticles. 

 ·   Nanoparticles (polymeric-based and liposomes) for MRI and Luminescence Imaging 

 ·   The Role of Innate-immunity in Restenosis and MI.  

 
An unexpected error has occurred.
 
 
 
 
​Laboratory Techniques  
 
Pharmaceutical formulations and compositions; dosage forms; dissolution and release kinetics; controlled / sustained release; animal models of restenosis and cancer; DSC/TG.   
 
 
An unexpected error has occurred.
 
 
 
 
Chapters in Books 
 
  • R.J. Levy, G. Golomb and R. Langer, Prevention of cardiovascular calcification with controlled-release diphosphonate. In: Artificial Organs, Proceedings of the International Symposium on Artificial Organs, Biomedical Engineering and Transplantation, J.D. Andrade, Ed., VCH Publishers, New York, 1987, pp. 657-669.
  •  
  • R.J. Levy, T.P. Johnston, A. Sintov and G. Golomb, Controlled release implants for cardiovascular disease. In: Advances in Drug Delivery Systems, J.M. Anderson, S.W. Kim and K. Knutson, Eds., Elsevier Science Publications, Amsterdam, 1990, pp. 245-255.
  •  
  • R.J. Levy, S.F. Bolling, R. Siden, A. Kadish, Y. Patak, P. Dorostkar, A. Sintov, G. Golomb and T.P. Johnston, Polymeric controlled release of cardiovascular drugs. In: Cosmetic and Pharmaceutic Polymer Applications, C. Gebelein, T.C. Cheng and V.C. Yang, Eds., Plenum Press, NY, 1991, pp. 231-238.
  •  
  • R.J. Levy, G. Golomb, V. Labhasetwar, New frontiers in cardiovascular polymeric controlled release. Polymeric Materials Science and Engineering 66, 492 (1992).
  •  
  • R.J. Levy, G. Golomb, J. Trachy, V. Labhasetwar, D. Muller and E. Topol, Strategies for treating arterial restenosis using polymeric controlled release implants. In: Biotechnology and Bioactive Polymers, C.G. Gebelein, Ed., Edgewater, FL: Lionfire, Inc., 1994, pp. 259-268.
  •  
  • G. Golomb, M. Mayberg and A.J. Domb, Polymeric perivascular delivery systems. In: Polymeric Site-specific Pharmacotherapy, A.J. Domb, Ed., John Wiley & Sons, NY, 1994, pp. 206-219.
  •  
  • G. Golomb, D. Moscovitz, I. Fishbein and D. Mishaly, Perivascular polymeric controlled-release therapy. In: Encyclopedic Handbook of Biomaterials and Bioengineering, D. L. Wise, Ed., Marcel Dekker, NY, 1995, pp. 1043-1055.
  •  
  • J.M. Van Gelder and G. Golomb, The evaluation of bisphosphonates as potential drugs for calcium-related disorders. In: Animal models of human related calcium- metabolic disorders. A. Ornoy Ed., CRC Press, Boca Raton, 1995, pp. 181-206.
  •  
  • Theme Issue on Intrauterine Drug Delivery, G. Golomb, Ed., Adv. Drug Del. Rev. 17, 1995, pp. 149-204.
  •  
  • Fishbein, M. Chorny, I. Gati, L. Rabinovich and G. Golomb, Drug delivery systems for the treatment of restenosis, In: Biomaterials and Bioengineering Handbook, D.L. Wise, Ed., Marcel Dekker, NY, 2000, pp.313-335.
  •  
  • M. Chorny, H. Cohen-Sacks, I. Fishbein, H.D. Danenberg, and G. Golomb, Biodegradable nanoparticles as drug delivery systems for parenteral administration, Tissue Engineering and Novel Delivery Systems, M.J. Yaszemski et.al., Eds., Marcel Dekker, NY, 2004, 393-422.
  •  
  • E. Cohen-Sela, M. Chorny, and G. Golomb, Nanoparticles for Treatment of Restenosis. In: Nanoparticles for Pharmaceutical Applications, A. J. Domb, Y. Tabata, M. N. V. R. Kumar, S. Farber Eds., ASP, Stevenson Ranch, CA, 2006, pp.123-134.
  •  
  • H. Epstein, E. Afergan, N. Koroukhov, G. Eisenberg, D. Gutman and G. Golomb, Liposomal bisphosphonates for the treatment of restenosis. In: Liposome Technology, G. Gregoriadis Ed., 3rd ed., vol. II, Informa Healthcare, NY, 2007, pp. 187-206.
  •  
  • E. Cohen-Sela, V. Elazar, H. Epstein-Barash and G. Golomb, Nano-carriers of drugs and genes for the treatment of restenosis. In: Nanoparticulate Drug Delivery Systems, D. Thassu, M. Deleers and Y. Pathak, Eds., Informa Healthcare, NY, 2007, pp. 235-270.
  •  
  • E. Breuer, M.S. Chorghade, J. Fischer, and G. Golomb, Glossary of terms related to pharmaceutics (IUPAC Recommendations 2009), Pure Appl. Chem. 81, No. 5, pp. 971
  •  
  • M. Zepp, T.J. Bäuerle, V. Elazar, J. Peterschmitt, R. Lifshitz-Shovali, H. Adwan, F.P. Armbruster, G. Golomb and M.R. Berger, Treatment of breast cancer lytic skeletal metastasis using a model in nude rats. In: Breast Cancer - Current and Alternative Therapeutic Modalities, E. Gunduz and M. Gunduz Eds., InTech OpenAccess, 2011, pp. 453-488.
  •  
  • D. Gutman, H. Epstein-Barash, M. Tsuriel and G. Golomb. Alendronate liposomes for antitumor therapy: Activation of T cells and inhibition of tumor growth. In: Nano-biotechnology for Biomedical and Diagnostic Research (Advances in Experimental Medicine and Biology), E. Zahavy, A. Ordentlich, S. Yitzhaki and A. Shaffermaned Eds., Springer, 2011, pp. 165-180.
  •  
  • D. Gutman and G. Golomb, Liposomal alendronate for the treatment of restenosis, J. Control. Release (in press)
  •  
     
    An unexpected error has occurred.
     
      
     
     
     Patents (>29) 
     
     
     
     
    An unexpected error has occurred.
website by Bynet Software Systems